STIM

Neuronetics, Inc. (STIM) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Neuronetics, Inc. is a global leader in neuroscience, primarily known for the NeuroStar Advanced Therapy System for treating major depressive disorder (MDD). A material development in this period is the full consolidation of Greenbrook TMS Inc., acquired on December 9, 2024, which significantly expanded the company's direct clinic revenue stream. The company operates as a single segment focused on TMS products and clinical services.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Surge: Revenue increased 132% year-over-year in Q2 and 107% year-over-year for the six months ended June 30, 2025. This growth is primarily driven by the inclusion of $23.0 million in clinic revenue from Greenbrook in Q2 2025.
• Mix Shift and Margin Compression: Gross margin declined significantly from 74.0% to 46.6% in Q2. This is attributed to the lower-margin profile of the acquired clinic business compared to the high-margin treatment session sales, alongside a decrease in NeuroStar system sales volume (41 systems in Q2 2025 vs. 49 in Q2 2024).
• Expense Increases: General and Administrative (G&A) expenses nearly doubled (up 98% in Q2) due to the consolidation of Greenbrook's overhead. Sales and Marketing expenses remained relatively flat, while R&D expenses decreased by 20% due to restructuring efficiencies.
• Capital Raise: In February 2025, the company completed a secondary public offering, issuing 9.2 million shares for net proceeds of approximately $18.9 million.

Outlook, Risks, and Management Commentary

• Liquidity Position: Management believes current cash ($11.0 million) and anticipated revenues are sufficient to fund operations for at least the next 12 months. However, the company has an accumulated deficit of $442.6 million and continues to incur operating losses.
• Debt Covenants: The company has $60.0 million outstanding under the Perceptive Credit Facility, maturing in July 2029. The facility includes a minimum trailing revenue covenant and a minimum liquidity covenant. The company was in compliance as of June 30, 2025.
• Subsequent Events:
  • On July 3, 2025, the company entered an "at-the-market" (ATM) equity distribution agreement for up to $50.0 million.
  • On August 1, 2025, the company amended its credit facility to borrow an additional $10.0 million (Tranche 2A) and lowered the minimum liquidity requirement to $2.0 million through September 2026.
  • Steven Pfanstiel was appointed Executive Vice President and Chief Financial Officer on July 15, 2025.
• Risks: Key risks include the ability to achieve cash flow breakeven (targeted for Q3 2025), reliance on third-party payor reimbursement rates for clinic revenue, and the need for additional capital if revenue growth does not materialize as projected.

Investor Verification Checklist

• Revenue Quality: Verify the sustainability of the new clinic revenue stream and the impact of third-party payor reimbursement rates on future margins.
• Cash Burn Rate: Monitor the trajectory of operating cash flow losses against the $11.0 million cash balance to assess runway without further dilution.
• Debt Compliance: Track adherence to the Perceptive Facility's minimum revenue and liquidity covenants, especially given the recent amendment lowering liquidity requirements.
• Product Sales: Analyze the decline in NeuroStar system unit sales (41 units in Q2 2025 vs. 49 in Q2 2024) to determine if this is a temporary market fluctuation or a structural shift.
• Integration Synergies: Assess whether the projected cost efficiencies from the Greenbrook acquisition are materializing to offset the increased G&A expenses.